References
  1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol 2020; 16:223-237.
  2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.Lancet 2021; 398:957-980.
  3. Martínez-Rueda AJ, Olivas-Martínez A, Vega-Vega O, Fonseca-Correa JI, Correa-Rotter R. New 2017 American College of Cardiology / American Heart Association High Blood Pressure Guideline. Hypertension 2019; 73: 142-147.
  4. Chatelanat O, Pechère-Bertschi A, Ponte B. Sensibilité au sel et hypertension artérielle [Salt sensitivity and hypertension]. Rev Med Suisse2019;15:1625-1628.
  5. Di Palo KE, Barone NJ. Hypertension and Heart Failure: Prevention, Targets, and Treatment.Heart Fail Clin 2020; 16:99-106.
  6. Cuka E, Simonini M, Lanzani C, Zagato L, Citterio L, Messaggio E, et al . Inverse salt sensitivity: an independent risk factor for cardiovascular damage in essential hypertension. J Hypertens 2022; 40:1504-1512.
  7. Garfinkle MA. Salt and essential hypertension: pathophysiology and implications for treatment. J Am Soc Hypertens 2017; 11:385-391.
  8. Kuchulakanti PK. ARNI in cardiovascular disease: current evidence and future perspectives.Future Cardiol 2020; 16:505-515.
  9. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al . 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136:e137-e161.
  10. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18:891-975.
  11. Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment. Hypertens Res 2021; 44:1239-1250.
  12. Wang TD, Tan RS, Lee HY, Ihm SH, Rhee MY, Tomlinson B, et al . Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.Hypertension 2017; 69:32-41.
  13. Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, et al . Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.Hypertension 2017; 69:411-420.
  14. Supasyndh O, Wang J, Hafeez K, Zhang Y, Zhang J, Rakugi H. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension. Am J Hypertens 2017; 30:1163-1169.
  15. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.Lancet 2010; 375:1255-1266.
  16. Ye L, Wang J, Chen Q, Yang X. LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials). Oncotarget2017; 8:107991-108005.
  17. Sun J, Xu W, Hua H, Xiao Y, Chen X, Gao Z, et al . Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.Biomed Pharmacother 2020; 129:110410.
  18. Hu Y, Zhang H, Li X, Mai J, Yang L, Yan J, et al . A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers.Expert Opin Investig Drugs 2021; 8:1-9.
  19. Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, et al . Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Br J Pharmacol 2018; 175:987-993.
  20. Morris CJ, Hastings JA, Boyd K, Krainski F, Perhonen MA, Scheer FA, et al . Day/night variability in blood pressure: influence of posture and physical activity. Am J Hypertens 2013; 26:822-830.
  21. Parati G, Staessen JA. Day-night blood pressure variations: mechanisms, reproducibility and clinical relevance. J Hypertens 2007; 25:2377-2380.
  22. Acosta J, Bussi IL, Esquivel M, Höcht C, Golombek DA, Agostino PV. Circadian modulation of motivation in mice. Behav Brain Res 2020; 382:112471.
  23. Tahara Y, Aoyama S, Shibata S. The mammalian circadian clock and its entrainment by stress and exercise. J Physiol Sci 2017; 67:1-10.
  24. Carmichael CY, Wainford RD. Hypothalamic signaling mechanisms in hypertension. Curr Hypertens Rep 2015; 17:39.
  25. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302:237-243.
  26. Han Y, Ayalasomayajula S, Pan W, Yang F, Yuan Y, Langenickel T, et al . Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. Eur J Drug Metab Pharmacokinet 2017; 42:109-116.
  27. Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC. Sacubitril/valsartan: beyond natriuretic peptides. Heart. 2017 Oct;103(20):1569-1577. doi: 10.1136/heartjnl-2017-311295. Epub 2017 Jul 8. PMID: 28689178.
  28. Campbell HT, Lightfoot BO, Sklar AH. Four-hour atrial natriuretic peptide infusion in conscious rats: effects on urinary volume, sodium, and cyclic GMP. Proc Soc Exp Biol Med 1988; 189:317-324.
  29. Wong PC, Hart SD, Duncia JV, Timmermans PB. Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs. Eur J Pharmacol. 1991 Sep 24;202(3):323-30. doi: 10.1016/0014-2999(91)90274-t. PMID: 1748155.
  30. Salazar J, Rojas-Quintero J, Cano C, Pérez JL, Ramírez P, Carrasquero R, et al . Neprilysin: A Potential Therapeutic Target of Arterial Hypertension? Curr Cardiol Rev 2020; 16:25-35.
  31. Tabrizchi R. Omapatrilat. Bristol-Myers Squibb. Curr Opin Investig Drugs 2001; 2:1414-1422.
  32. Dzielska-Olczak M. Omapatrilat–nowy lek dla chorych na nadciśnienie tetnicze i niewydolność serca [Omapatrilat–new drug for patients with hypertension and heart failure]. Pol Merkur Lekarski 2005; 19:556-563.
  33. Kim H, Jang S, Kim IW. Enhanced Dissolution of Naproxen by Combining Cocrystallization and Eutectic Formation. Pharmaceutics 2021; 13:618.
  34. Cysewski P. In silico screening of dicarboxylic acids for cocrystallization with phenylpiperazine derivatives based on both cocrystallization propensity and solubility advantage. J Mol Model 2017; 23:136.